<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01951326</url>
  </required_header>
  <id_info>
    <org_study_id>RHB-104-01</org_study_id>
    <nct_id>NCT01951326</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease</brief_title>
  <acronym>MAPUS</acronym>
  <official_title>A Randomized, Double Blind, Placebo-controlled, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Fixed-dose Combination RHB-104 in Subjects With Moderately to Severely Active Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RedHill Biopharma Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RedHill Biopharma Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that RHB-104 will have greater efficacy than placebo in Crohn's
      disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Randomized, Double Blind, Placebo-controlled, Multicenter, Parallel Group Study to Assess
      the Efficacy and Safety of Fixed-dose Combination RHB-104 in Subjects with Moderately to
      Severely Active Crohn's Disease.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">August 2019</completion_date>
  <primary_completion_date type="Actual">May 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Remission at Week 26</measure>
    <time_frame>Week 26</time_frame>
    <description>Reduction of the total Crohn's Disease Activity Index (CDAI) score to less than 150. Lower CDAI scores indicate a better outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response at Week 26</measure>
    <time_frame>Week 26</time_frame>
    <description>Reduction of Crohn's Disease Activity Index (CDAI) score by a minimum of 100 points. Lower CDAI scores indicate a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission at Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>Reduction of the total Crohn's Disease Activity Index (CDAI) score to less than 150. Lower CDAI scores indicate a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Durable Remission Week 26 Through Week 52</measure>
    <time_frame>Week 26 through week 52</time_frame>
    <description>When a subject is in remission with a maximum CDAI score of 149 at every visit from Week 26 through and including Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>Reduction of the total Crohn's Disease Activity Index (CDAI) score to less than 150. Lower CDAI scores indicate a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steroid Free Remission at Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>Subjects who are maintained off steroids for a minimum of 3 weeks</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Duration of Remission</measure>
    <time_frame>Baseline through week 52</time_frame>
    <description>Number of weeks that a subject is in a state of remission. Subjects who experienced remission and continued to be in remission at the time of their last CDAI assessment are censored at the date of their last CDAI assessment.</description>
  </other_outcome>
  <other_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Baseline through week 52</time_frame>
    <description>Number of weeks a subject is in a state of response. Subjects who experienced response and continued to be in response at the time of their last CDAI assessment are censored at the date of their last CDAI assessment.</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to Remission</measure>
    <time_frame>Baseline through week 52</time_frame>
    <description>[Date of first observed remission (CDAI score &lt; 150) - Date of first dose or date of randomization if not dosed + 1] / 7 Days. Subjects who never experienced remission during the study are censored at the date of their last CDAI assessment.</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to Response</measure>
    <time_frame>Baseline through week 52</time_frame>
    <description>[Date of first observed response (a reduction from baseline of ≥ 100 in CDAI score) - Date of first dose or date of randomization if not dosed + 1] / 7 Days. Subjects who never experienced response during the study are censored at the date of their last CDAI assessment.</description>
  </other_outcome>
  <other_outcome>
    <measure>Durable Remission Week 16 Through Week 52</measure>
    <time_frame>Week 16 through week 52</time_frame>
    <description>Remission in a subject from week 16 through week 52.</description>
  </other_outcome>
  <other_outcome>
    <measure>Response at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>Reduction of Crohn's Disease Activity Index (CDAI) score by a minimum of 100 points. Lower CDAI scores indicate a better outcome.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cardiac Safety</measure>
    <time_frame>Week 26</time_frame>
    <description>Change-from-baseline to week 26 in QTcF (based on cardiac safety report)</description>
  </other_outcome>
  <other_outcome>
    <measure>Cardiac Safety</measure>
    <time_frame>Baseline through week 52</time_frame>
    <description>Placebo-corrected change-from-baseline to week 52 in QTcF (based on cardiac safety report)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">331</enrollment>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>RHB-104</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5 RHB-104 capsules administered orally BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>5 placebo capsules administered orally BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RHB-104</intervention_name>
    <description>95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine</description>
    <arm_group_label>RHB-104</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>5 placebo capsules administered orally BID</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Signed fully informed consent provided as per this protocol.

          2. Diagnosis of Crohn's Disease confirmed by endoscopy or radiography and/or histology at
             least 6 months prior to randomization into the study.

          3. CD involving the ileum and/or colon

          4. Moderately to severely active CD (Crohn's Disease Activity Index (CDAI) score of
             greater than or equal to 220 and less than or equal to 450) at baseline.

          5. Current treatment with at least one of the following therapies:

             A. Oral 5-acetyl salicylic acid (5-ASA) compounds. Dose must be stable for at least 4
             weeks before baseline.

             B. Corticosteroid therapy. Dose must be stable for at least 2 weeks before baseline.

             C. Azathioprine or 6-mercaptopurine (6-MP) or methotrexate. Dose must be stable for at
             least 8 weeks before baseline.

             D. Infliximab or adalimumab. Dose must be stable for at least 14 weeks before
             baseline.

          6. White blood cell count greater than or equal to 3.5 x 109 at screening.

          7. Active Crohn's disease, defined by at least one of the following: C-reactive protein
             greater than Upper Limit of Normal (ULN) at screening, fecal calprotectin greater than
             Upper Limit of Normal (ULN) at screening, OR radiographic (MRE or CTE) or endoscopic
             confirmation of the presence of active CD within 5 weeks of screening visit. .

          8. Subject agrees to use barrier contraceptive methods (i.e. diaphragm, cervical cap,
             contraceptive sponge or condom) with spermicidal foam/gel/cream/suppository, IUD/IUS
             or progestogen injection (Depo-Provera®) throughout the study and for at least 6 weeks
             after last study drug administration, unless subject is post-menopausal or otherwise
             incapable of becoming pregnant by reason of surgery or tubal ligation, or has had a
             vasectomy. In regions where local regulatory contraceptive requirements differ, the
             ICF will reflect local policies.

        Exclusion Criteria

          1. Crohn's Disease involvement isolated to the mouth, upper gastrointestinal tract, or
             anus.

          2. History of total colectomy with ileorectal anastomosis or a proctocolectomy.

          3. Presence of active fistulizing Crohn's Disease or healed fistula within 2 months prior
             to screening.

          4. Subject has postoperative stoma, ostomy, or ileoanal pouch.

          5. Subject has short bowel syndrome.

          6. Subject is scheduled for surgical bowel resection.

          7. Subject has known symptomatic obstructive strictures or bowel perforation in the 6
             months prior to screening.

          8. Change in dose or discontinuation of oral 5-acetyl salicylic acid (5-ASA) compounds
             less than 4 weeks prior to baseline.

          9. Change in dose or discontinuation of corticosteroids less than 2 weeks prior to
             baseline.

         10. Change in dose or discontinuation of azathioprine, 6-mercaptopurine (6-MP) or
             methotrexate less than 8 weeks prior to baseline.

         11. Change in dose or discontinuation of infliximab or adalimumab less than 14 weeks prior
             to baseline.

         12. Treatment with vedolizumab less than 120 days prior to baseline or biological
             therapies (apart from infliximab or adalimumab) less than 60 days prior to baseline.

         13. Previous treatment with rifabutin and/or clofazimine.

         14. Oral or parenteral antibiotics in the 4 weeks prior to baseline (topical antibiotics
             are permitted).

         15. Treatment with probiotics (excluding yogurt and yogurt-derived products) in the 4
             weeks prior to baseline.

         16. Females who have a positive pregnancy test or are lactating.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ira N Kalfus, MD</last_name>
    <role>Study Director</role>
    <affiliation>RedHill Biopharma</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Y. Graham, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Medicine/Gastroenterology, Baylor College of Medicine, Houston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Del Sol Research Management, 850 N Knob Road</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associated Gastroenterology Medical Group, 1211 W. La Palmak Ave, Suite 303</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medvin Clinical Research, 15627 Imperial Highway,</name>
      <address>
        <city>La Mirada</city>
        <state>California</state>
        <zip>90638</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Digestive Care Associates, Inc., 1000 Laurel St.</name>
      <address>
        <city>San Carlos</city>
        <state>California</state>
        <zip>94070</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ventura Clinical Trials, 1835 Knoll Drive</name>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Research Center of Connecticut, LLC</name>
      <address>
        <city>Hamden</city>
        <state>Connecticut</state>
        <zip>06518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovative Medical Research of South Florida, 2999 NE 191 St., Suite 330</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of West Florida</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunrise Medical Research, Inc. 4700 N. State Road Building A, Suite 111</name>
      <address>
        <city>Lauderdale Lakes</city>
        <state>Florida</state>
        <zip>33319</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Group of Naples, 1064 Goodlette Road</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Research Institute Inc., 7114 Congress Street</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endoscopic Research, Inc., 1817 North Mills Avenue</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Medical Research Center, 1690 Dunlawton Ave., Suite 110</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Center for Gastroenterology 2665 North Decatur Road Suite 550</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastrointestinal Specialists of Georgia PC, 711 Canton Rd. Suite 300</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Carle Foundation, 611 West Park Street</name>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cotton-O'Neil Clinical Research Center, 720 SW Lane St.</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Clinical Research, 612 Ridgely Avenue, Suite 401,</name>
      <address>
        <city>Annapolis</city>
        <state>Maryland</state>
        <zip>21401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chevy Chase Clinical Research, 5550 Friendship Blvd.</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Commonwealth Clinical Studies, 189 Quincy St.</name>
      <address>
        <city>Brockton</city>
        <state>Massachusetts</state>
        <zip>02302-2926</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center For Digestive Health</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Michigan Clinical Research Center, 2093 Health Dr. SW, Suite 201</name>
      <address>
        <city>Wyoming</city>
        <state>Michigan</state>
        <zip>49519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ehrhardt Clinical Research, LLC, 108 Congress Street</name>
      <address>
        <city>Belton</city>
        <state>Missouri</state>
        <zip>64012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AGA Clinical Research Associates, Inc., 3205 Fire Road</name>
      <address>
        <city>Egg Harbor Township</city>
        <state>New Jersey</state>
        <zip>08324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holy Name Medical Center, 718 Teaneck Road</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <zip>07666</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center, 111 East 210th Street</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore Long Island Jewish Medical Group, 600 Northern Boulevard, Suite 111</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Langone Long Island , 1000 Northern Boulevard, Suite 160</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manhattan Medical Research Practice PLLC, 215 Lexington Avenue, 21st Floor</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina Center for inflammatory Bowel Diseases, CB 7080, 130 Mason Farm Road, 4151 Bioinformatics Bldg.</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio GI and Liver Institute, 2925 Vernon Place 100</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio GI and Liver Institute</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinSearch, 6035 Shallowford Road, Suite 109</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brooke Army Medical Center, 3551 Roger Brooke Drive</name>
      <address>
        <city>Fort Sam Houston</city>
        <state>Texas</state>
        <zip>78284</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine, 7200 Cambridge Street Suite 180.184, 10th Floor</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Sciences Center at Houston, 6431 Fannin Street, Medical School Bldg 4-234</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spring Gastroenterology Associates, 8901 FM 1960 West</name>
      <address>
        <city>Humble</city>
        <state>Texas</state>
        <zip>77036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DHAT Research Institute / Digestive Health Associates of Texas 3600 Shire Blvd, Suite 106</name>
      <address>
        <city>Richardson</city>
        <state>Texas</state>
        <zip>75082</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Digestive Disease Center, 621 Camden Street, Suite 202</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tyler Research Institute, 1720 S. Beckham</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gasteroenterology Associates of Northern Virgina, 3028 Javier Road</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGuire DVAMC, 1201 Broad Rock Boulevard</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bankstown Hospital, Level 3, Department of Gastroenterology, Eldridge Road</name>
      <address>
        <city>Bankstown</city>
        <state>New South Wales</state>
        <zip>2200</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Gastroenterology and Hepatology, Concord Hospital, Hospital Road</name>
      <address>
        <city>Concord</city>
        <state>New South Wales</state>
        <zip>2139</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nepean Hospital, Derby Street</name>
      <address>
        <city>Kingswood</city>
        <state>New South Wales</state>
        <zip>2747</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Gastroenterology, Level 1, Clinic 123, New Clinical Building, Liverpool Hospital, Elizabeth St.</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Gastroenterology and Hepatology, Level 9, Ned Hanlon Building, Royal Brisbane and Women's Hospital Corner Butterfield Street and Bowen Bridge Street</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mater Hospital Brisbane, Department of Gastroenterology, Raymond Terrace</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ballarat Health Services, Drummond St North</name>
      <address>
        <city>Ballarat</city>
        <state>Victoria</state>
        <zip>3350</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Gastroenterology, Eastern Health, ECRU, Level 2, 5 Arnold Street</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Gastroenterology and Hepatology, Cabrini Medical Centre, 183 Wattletree Road</name>
      <address>
        <city>Malvern</city>
        <state>Victoria</state>
        <zip>3144</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT &quot;Sv. Karidad&quot; EAD, Department of Internal Medicine / Gastroenterology, endocrinology and metabolic disorders, 23А, Nikola Vaptsarov Blvd</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT &quot;Hadzhi Dimitar&quot; OOD, Department of Internal Medicine / Gastroenterology and Endocrinology, 5, Dimitar Pehlivanov str.</name>
      <address>
        <city>Sliven</city>
        <zip>8800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMHAT &quot;Sv. Ivan Rilski&quot; EAD; Clinic of Gastroenterology, 15, Akad. Ivan Geshov Blvd.,</name>
      <address>
        <city>Sofia</city>
        <zip>1432</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ACIBADEM CITY CLINIC UNIVERSITY HOSPITAL EOOD, Oncology Center, Clinic of Gastroenterology, 66 A, Tsarigradsko shosse Blvd</name>
      <address>
        <city>Sofia</city>
        <zip>1784</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DCC &quot;Mladost-M Varna&quot; OOD, office 528 V, 15, Republika Blvd.</name>
      <address>
        <city>Varna</city>
        <zip>9020</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Discovery Clinical Services Ltd. 601 A Discovery St.</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8T 5G4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital, 600 University Avenue, Suite 445</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal General Hospital Digestive Lab Research Institute McGill University Health Center, 1650 Cedar Avenue C10.145</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3G 1A4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Saskatchewan Royal University Hospital, 103 Hospital Drive IBD Clinical Trials Unit Rm 2658</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnice Horovice, NH Hospital, a.s., Chirurgicke oddeleni, K Nemocnici 1106</name>
      <address>
        <city>Horovice</city>
        <zip>268 31</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterologie s.r.o., Manesova 646,</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 02</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HEPATO-GASTROENTEROLOGIE HK, s.r.o., Trida Edvarda Benese 1549/34</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>50012</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EGK s.r.o., Sanatorium sv. Anny, Gastroenterologicke oddeleni, Lucni 7a/2776,</name>
      <address>
        <city>Praha 3</city>
        <zip>13000</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IBD centrum / ISCARE IVF a.s., Jankovcova 1569/2c</name>
      <address>
        <city>Praha</city>
        <zip>17000</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ARTROSCAN, s.r.o., Gastroenterologicka ambulance, 5114 Trebovicka, Ostrava</name>
      <address>
        <city>Trebovice</city>
        <zip>722 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krajska zdravotni, a.s., Masarykova nemocnice o.z. Gastroenterologie, Socialni pece 3316/12A</name>
      <address>
        <city>Usti nad Labem</city>
        <zip>401 13</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Assaf HaRofeh Medical Center, Gastroenterology Department, Harofeh Medical Center</name>
      <address>
        <city>Be'er Ya'aqov</city>
        <zip>70300</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bnaizion Medical Center, Golomb 47</name>
      <address>
        <city>Haifa</city>
        <zip>31048</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The E. Wolfson Medical Center, 62 Halohamim Str.</name>
      <address>
        <city>Holon</city>
        <zip>58100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center, Beith Street</name>
      <address>
        <city>Jerusalem</city>
        <zip>91031</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ein Karem Medical Center, Kiryat Hadassah</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meir, 59 Tchemacovsky St</name>
      <address>
        <city>Kfar-Saba</city>
        <zip>44281</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galilee Medical Center, P.O.B. 21</name>
      <address>
        <city>Nahariya</city>
        <zip>1210001</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holy Family Hospital, Namsawi St. POB 8</name>
      <address>
        <city>Nazareth</city>
        <zip>16100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RMC Beilinson Hospital, 39 Jabotinsky Street</name>
      <address>
        <city>Petach-Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sourasky Medical Center, 6 Weizman Street</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shakespeare Specialist Group, North Shore, Suite 3, 181 Shakespeare Road, Milford Takapuna</name>
      <address>
        <city>Auckland</city>
        <zip>0620</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christchurch Hospital</name>
      <address>
        <city>Christchurch</city>
        <zip>4710</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Unit, Southern District Health Board, 201 Great King Street,</name>
      <address>
        <city>Dunedin</city>
        <zip>9054</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Gastroenterology,Waikato Hospital</name>
      <address>
        <city>Hamilton</city>
        <zip>3240</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Unit, Tauranga Hospital,</name>
      <address>
        <city>Tauranga</city>
        <zip>3112</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Specjalistyczne Centrum Gastrologii GASTROMED Wiejska 81</name>
      <address>
        <city>Bialystok</city>
        <zip>15-351</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SP ZOZ MSWiA w Gdańsku, Oddział Gastroenterologiczny, ul. Kartuska 4/6</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-104</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNICARDIA Specjalistyczne Centrum Leczenia Chorob Serca i Naczyn &amp; UNIMEDICA Specjalistyczne Centrum Medyczne Sp. z o.o. Kluczborska 15</name>
      <address>
        <city>Krakow</city>
        <zip>31-271</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Kliniczny w Olsztynie Oddzial Gastroenterologiczny Żołnierska 18</name>
      <address>
        <city>Olsztyn</city>
        <zip>10-561</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ENDOSKOPIA sp. z o.o. B. Chrobrego 6/8</name>
      <address>
        <city>Sopot</city>
        <zip>81-756</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EuroMedis sp. z.o.o., ul. Powstanców Wielkopolskich 33a</name>
      <address>
        <city>Szczecin</city>
        <zip>70-111</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;GASTROMED&quot; Kopon, Zmudzinski i wspolnicy sp. j., Specjalistyczne Centrum Gastroskopii i Endoskopii, Specjalistyczne Gabinety Lekarskie Grudziadzka 11</name>
      <address>
        <city>Torun</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centralny Szpital Kliniczny MSW w Warszawie Klinika Chorob Wewnetrznych i Gastroenterologii Woloska 137</name>
      <address>
        <city>Warszawa</city>
        <zip>02-507</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ARS MEDICA s.c. Rybak Maria, Rybak Zbigniew, Powstancow Slaskich 56A/2</name>
      <address>
        <city>Wroclaw</city>
        <zip>53-333</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Szpital Sw. Rodziny Sp. z o.o. Wigury 19</name>
      <address>
        <city>Łódź</city>
        <zip>90-302</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>: Clinic for Gastroenterology and Hepatology, Clinical Center of Serbia Koste Todorovica 2</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Department of Gastroenterology and Hepatology, Clinic for Internal Diseases, Clinical Hospital Center Zvezdara Dimitrija Tucovica 161</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Gastroenterology and Hepatology, Clinical Hospital Center Zemun Vukova 9</name>
      <address>
        <city>Belgrade</city>
        <zip>11080</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>: Center for Gastroenterohepatology, Clinic for Internal Medicine, Clinical Center of Kragujevac Zmaj Jovina 30</name>
      <address>
        <city>Kragujevac</city>
        <zip>34000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>: Clinic of Gastroenterology and Hepatology, Clinical Center of Vojvodina Hajduk Veljkova 1</name>
      <address>
        <city>Novi Sad</city>
        <zip>21000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univerzitna nemocnica Bratislava - Nemocnica Ružinov, V. Interná klinika LFUK a UNB, Gastroenterologické a hepatologické oddelenie, Ruzinovska 6</name>
      <address>
        <city>Bratislava</city>
        <zip>82606</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univerzitná nemocnica Bratislava - Nemocnica sv. Cyrila a Metoda Gastroenterologická klinika SZU a UNB Antolská 11</name>
      <address>
        <city>Bratislava</city>
        <zip>851 07</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Breznianske centrum gastroenterologie, s.r.o. Banisko 1</name>
      <address>
        <city>Brezno</city>
        <zip>97701</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PIGEAS s.r.Prieložtek 1, o.,</name>
      <address>
        <city>Martin</city>
        <zip>036 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KM Management spol. s.r.o., Gastroenterologické a hepatologické centrum Nitra, Špitálska 13</name>
      <address>
        <city>Nitra</city>
        <zip>949 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Israel</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>http://www.redhillbio.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>September 19, 2013</study_first_submitted>
  <study_first_submitted_qc>September 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2013</study_first_posted>
  <results_first_submitted>March 29, 2020</results_first_submitted>
  <results_first_submitted_qc>April 21, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">May 1, 2020</results_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Crohn's Disease</keyword>
  <keyword>moderate to severe</keyword>
  <keyword>remission</keyword>
  <keyword>MAP</keyword>
  <keyword>antibiotic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 5, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/26/NCT01951326/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 29, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/26/NCT01951326/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>RHB-104</title>
          <description>5 RHB-104 capsules administered orally BID
RHB-104: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>5 placebo capsules administered orally BID
Placebo: 5 placebo capsules administered orally BID</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="166"/>
                <participants group_id="P2" count="165"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
                <participants group_id="P2" count="87"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
                <participants group_id="P2" count="78"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>RHB-104</title>
          <description>5 RHB-104 capsules administered orally BID
RHB-104: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>5 placebo capsules administered orally BID
Placebo: 5 placebo capsules administered orally BID</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="166"/>
            <count group_id="B2" value="165"/>
            <count group_id="B3" value="331"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.0" spread="12.51"/>
                    <measurement group_id="B2" value="39.3" spread="12.56"/>
                    <measurement group_id="B3" value="39.1" spread="12.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="142"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="156"/>
                    <measurement group_id="B2" value="150"/>
                    <measurement group_id="B3" value="306"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Southeast Asia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>North America</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Crohn's Disease Activity Index (CDAI) score</title>
          <description>Generally, CDAI scores can range from 0 to ~600. (in this protocol up to 450)
CDAI scores of 150–219 describe mildly active disease, while scores of 220–450 describe moderately active disease and scores above 450 describe severe disease.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="297.77" spread="57.023"/>
                    <measurement group_id="B2" value="293.44" spread="53.184"/>
                    <measurement group_id="B3" value="295.61" spread="55.102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Anti-TNF Use at Baseline</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Remission at Week 26</title>
        <description>Reduction of the total Crohn's Disease Activity Index (CDAI) score to less than 150. Lower CDAI scores indicate a better outcome.</description>
        <time_frame>Week 26</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RHB-104</title>
            <description>5 RHB-104 capsules administered orally BID
RHB-104: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>5 placebo capsules administered orally BID
Placebo: 5 placebo capsules administered orally BID</description>
          </group>
        </group_list>
        <measure>
          <title>Remission at Week 26</title>
          <description>Reduction of the total Crohn's Disease Activity Index (CDAI) score to less than 150. Lower CDAI scores indicate a better outcome.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0048</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified according to anti-TNF agent use (Y/N).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response at Week 26</title>
        <description>Reduction of Crohn's Disease Activity Index (CDAI) score by a minimum of 100 points. Lower CDAI scores indicate a better outcome.</description>
        <time_frame>Week 26</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RHB-104</title>
            <description>5 RHB-104 capsules administered orally BID
RHB-104: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>5 placebo capsules administered orally BID
Placebo: 5 placebo capsules administered orally BID</description>
          </group>
        </group_list>
        <measure>
          <title>Response at Week 26</title>
          <description>Reduction of Crohn's Disease Activity Index (CDAI) score by a minimum of 100 points. Lower CDAI scores indicate a better outcome.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0116</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified according to anti-TNF agent use (Y/N).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Remission at Week 52</title>
        <description>Reduction of the total Crohn's Disease Activity Index (CDAI) score to less than 150. Lower CDAI scores indicate a better outcome.</description>
        <time_frame>Week 52</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RHB-104</title>
            <description>5 RHB-104 capsules administered orally BID
RHB-104: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>5 placebo capsules administered orally BID
Placebo: 5 placebo capsules administered orally BID</description>
          </group>
        </group_list>
        <measure>
          <title>Remission at Week 52</title>
          <description>Reduction of the total Crohn's Disease Activity Index (CDAI) score to less than 150. Lower CDAI scores indicate a better outcome.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0616</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified according to anti-TNF agent use (Y/N).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Durable Remission Week 26 Through Week 52</title>
        <description>When a subject is in remission with a maximum CDAI score of 149 at every visit from Week 26 through and including Week 52</description>
        <time_frame>Week 26 through week 52</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RHB-104</title>
            <description>5 RHB-104 capsules administered orally BID
RHB-104: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>5 placebo capsules administered orally BID
Placebo: 5 placebo capsules administered orally BID</description>
          </group>
        </group_list>
        <measure>
          <title>Durable Remission Week 26 Through Week 52</title>
          <description>When a subject is in remission with a maximum CDAI score of 149 at every visit from Week 26 through and including Week 52</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0851</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified according to anti-TNF agent use (Y/N).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Remission at Week 16</title>
        <description>Reduction of the total Crohn's Disease Activity Index (CDAI) score to less than 150. Lower CDAI scores indicate a better outcome.</description>
        <time_frame>Week 16</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RHB-104</title>
            <description>5 RHB-104 capsules administered orally BID
RHB-104: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>5 placebo capsules administered orally BID
Placebo: 5 placebo capsules administered orally BID</description>
          </group>
        </group_list>
        <measure>
          <title>Remission at Week 16</title>
          <description>Reduction of the total Crohn's Disease Activity Index (CDAI) score to less than 150. Lower CDAI scores indicate a better outcome.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0147</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified according to anti-TNF agent use (Y/N).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Steroid Free Remission at Week 52</title>
        <description>Subjects who are maintained off steroids for a minimum of 3 weeks</description>
        <time_frame>Week 52</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RHB-104</title>
            <description>5 RHB-104 capsules administered orally BID
RHB-104: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>5 placebo capsules administered orally BID
Placebo: 5 placebo capsules administered orally BID</description>
          </group>
        </group_list>
        <measure>
          <title>Steroid Free Remission at Week 52</title>
          <description>Subjects who are maintained off steroids for a minimum of 3 weeks</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1510</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified according to anti-TNF agent use (Y/N).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Duration of Remission</title>
        <description>Number of weeks that a subject is in a state of remission. Subjects who experienced remission and continued to be in remission at the time of their last CDAI assessment are censored at the date of their last CDAI assessment.</description>
        <time_frame>Baseline through week 52</time_frame>
        <population>Reached duration of remission (dropped out of remission during the study), n (%): RHB-104 54 (53.5); Placebo: 49 (62.8). Censored (remain in remission during the study), n (%): RHB-104: 47 (46.5); Placebo 29 (37.2)</population>
        <group_list>
          <group group_id="O1">
            <title>RHB-104</title>
            <description>5 RHB-104 capsules administered orally BID
RHB-104: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>5 placebo capsules administered orally BID
Placebo: 5 placebo capsules administered orally BID</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Remission</title>
          <description>Number of weeks that a subject is in a state of remission. Subjects who experienced remission and continued to be in remission at the time of their last CDAI assessment are censored at the date of their last CDAI assessment.</description>
          <population>Reached duration of remission (dropped out of remission during the study), n (%): RHB-104 54 (53.5); Placebo: 49 (62.8). Censored (remain in remission during the study), n (%): RHB-104: 47 (46.5); Placebo 29 (37.2)</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.1" lower_limit="16.14" upper_limit="46.86"/>
                    <measurement group_id="O2" value="16.7" lower_limit="10.14" upper_limit="30.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2402</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Duration of Response</title>
        <description>Number of weeks a subject is in a state of response. Subjects who experienced response and continued to be in response at the time of their last CDAI assessment are censored at the date of their last CDAI assessment.</description>
        <time_frame>Baseline through week 52</time_frame>
        <population>Reached duration of response (dropped out of response during the study), n (%) RHB-104: 52 (45.2); Placebo: 55 (59.8). Censored (remain in response during the study), n (%): RHB-104: 63 (54.8); Placebo: 37 (40.2)</population>
        <group_list>
          <group group_id="O1">
            <title>RHB-104</title>
            <description>5 RHB-104 capsules administered orally BID
RHB-104: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>5 placebo capsules administered orally BID
Placebo: 5 placebo capsules administered orally BID</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response</title>
          <description>Number of weeks a subject is in a state of response. Subjects who experienced response and continued to be in response at the time of their last CDAI assessment are censored at the date of their last CDAI assessment.</description>
          <population>Reached duration of response (dropped out of response during the study), n (%) RHB-104: 52 (45.2); Placebo: 55 (59.8). Censored (remain in response during the study), n (%): RHB-104: 63 (54.8); Placebo: 37 (40.2)</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.1" lower_limit="22.14" upper_limit="52.29"/>
                    <measurement group_id="O2" value="22.1" lower_limit="12.14" upper_limit="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0460</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Time to Remission</title>
        <description>[Date of first observed remission (CDAI score &lt; 150) - Date of first dose or date of randomization if not dosed + 1] / 7 Days. Subjects who never experienced remission during the study are censored at the date of their last CDAI assessment.</description>
        <time_frame>Baseline through week 52</time_frame>
        <population>Number of subjects achieved remission, n (%) RHB-104: 101 (60.8); Placebo 78 (47.3). Censored, n (%): RHB-104: 65 (39.2); Placebo 87 (52.7)</population>
        <group_list>
          <group group_id="O1">
            <title>RHB-104</title>
            <description>5 RHB-104 capsules administered orally BID
RHB-104: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>5 placebo capsules administered orally BID
Placebo: 5 placebo capsules administered orally BID</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Remission</title>
          <description>[Date of first observed remission (CDAI score &lt; 150) - Date of first dose or date of randomization if not dosed + 1] / 7 Days. Subjects who never experienced remission during the study are censored at the date of their last CDAI assessment.</description>
          <population>Number of subjects achieved remission, n (%) RHB-104: 101 (60.8); Placebo 78 (47.3). Censored, n (%): RHB-104: 65 (39.2); Placebo 87 (52.7)</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.1" lower_limit="8.43" upper_limit="12.71"/>
                    <measurement group_id="O2" value="19.9" lower_limit="13.00" upper_limit="52.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0031</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Time to Response</title>
        <description>[Date of first observed response (a reduction from baseline of ≥ 100 in CDAI score) - Date of first dose or date of randomization if not dosed + 1] / 7 Days. Subjects who never experienced response during the study are censored at the date of their last CDAI assessment.</description>
        <time_frame>Baseline through week 52</time_frame>
        <population>Number of subjects achieved response, n (%): RHB-104: 115 (69.3); Placebo: 92 (55.8); Censored, n (%): RHB-104: 51 (30.7); Placebo: 73 (44.2)</population>
        <group_list>
          <group group_id="O1">
            <title>RHB-104</title>
            <description>5 RHB-104 capsules administered orally BID
RHB-104: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>5 placebo capsules administered orally BID
Placebo: 5 placebo capsules administered orally BID</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Response</title>
          <description>[Date of first observed response (a reduction from baseline of ≥ 100 in CDAI score) - Date of first dose or date of randomization if not dosed + 1] / 7 Days. Subjects who never experienced response during the study are censored at the date of their last CDAI assessment.</description>
          <population>Number of subjects achieved response, n (%): RHB-104: 115 (69.3); Placebo: 92 (55.8); Censored, n (%): RHB-104: 51 (30.7); Placebo: 73 (44.2)</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" lower_limit="8.00" upper_limit="9.14"/>
                    <measurement group_id="O2" value="12.1" lower_limit="8.14" upper_limit="15.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0100</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Durable Remission Week 16 Through Week 52</title>
        <description>Remission in a subject from week 16 through week 52.</description>
        <time_frame>Week 16 through week 52</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RHB-104</title>
            <description>5 RHB-104 capsules administered orally BID
RHB-104: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>5 placebo capsules administered orally BID
Placebo: 5 placebo capsules administered orally BID</description>
          </group>
        </group_list>
        <measure>
          <title>Durable Remission Week 16 Through Week 52</title>
          <description>Remission in a subject from week 16 through week 52.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0077</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified according to anti-TNF agent use (Y/N).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Response at Week 16</title>
        <description>Reduction of Crohn's Disease Activity Index (CDAI) score by a minimum of 100 points. Lower CDAI scores indicate a better outcome.</description>
        <time_frame>Week 16</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RHB-104</title>
            <description>5 RHB-104 capsules administered orally BID
RHB-104: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>5 placebo capsules administered orally BID
Placebo: 5 placebo capsules administered orally BID</description>
          </group>
        </group_list>
        <measure>
          <title>Response at Week 16</title>
          <description>Reduction of Crohn's Disease Activity Index (CDAI) score by a minimum of 100 points. Lower CDAI scores indicate a better outcome.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0422</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified according to anti-TNF agent use (Y/N).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Cardiac Safety</title>
        <description>Change-from-baseline to week 26 in QTcF (based on cardiac safety report)</description>
        <time_frame>Week 26</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RHB-104</title>
            <description>5 RHB-104 capsules administered orally BID
RHB-104: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>5 placebo capsules administered orally BID</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Safety</title>
          <description>Change-from-baseline to week 26 in QTcF (based on cardiac safety report)</description>
          <units>ms</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.8" lower_limit="25.91" upper_limit="29.74"/>
                    <measurement group_id="O2" value="0.2" lower_limit="-1.67" upper_limit="2.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Cardiac Safety</title>
        <description>Placebo-corrected change-from-baseline to week 52 in QTcF (based on cardiac safety report)</description>
        <time_frame>Baseline through week 52</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RHB-104</title>
            <description>5 RHB-104 capsules administered orally BID
RHB-104: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>5 placebo capsules administered orally BID</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Safety</title>
          <description>Placebo-corrected change-from-baseline to week 52 in QTcF (based on cardiac safety report)</description>
          <units>ms</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.8" lower_limit="27.57" upper_limit="32.02"/>
                    <measurement group_id="O2" value="-0.8" lower_limit="-3.16" upper_limit="1.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline through 30 days after last dose of study drug, or up to 13 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>RHB-104</title>
          <description>5 RHB-104 capsules administered orally BID
RHB-104: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>5 placebo capsules administered orally BID
Placebo: 5 placebo capsules administered orally BID</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorders</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General disorders and administration site conditions</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatobiliary disorders</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury, poisoning and procedural complications</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Investigations</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and urinary disorders</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Reproductive system and breast disorders</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular disorders</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="115" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="90" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Crohn's Disease</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Diarrheoa</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Abdominal tenderness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Viral Upper Respiratory Infections</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Clostridium difficile Infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Chromaturia</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Reza Fathi, Senior VP Research and Development</name_or_title>
      <organization>RedHill Biopharma</organization>
      <phone>972-(0)3-541-3131</phone>
      <email>reza@redhillbio.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

